NFE2L2 and non-small cell squamous lung carcinoma: Sapanisertib, a dual mTORC1/2 kinase inhibitor, was granted fast track designation by the FDA for patients with unresectable or metastatic squamous-cell non-small-cell lung cancer who have an NRF2 mutation.